Is Wall Street as prominent or alphabetic?

With the maximum market of $ 56.2 billion, becton, Dickinson and Company (BDX) is a global pioneer of medical technology that develops, manufactures and sells medical devices, laboratory equipment and diagnostic products. Its headquarters is located in Franklin Lakes, New Jersey and BD in health care institutions, life sciences and pharmaceutical industry around the world.

The shares of the manufacturer of medical devices have led to twice the broader market during the past 52 weeks. BDX shares decreased by 16.8 % during this time frame, while the broader S&P 500 index ($ SPX) gained 16.1 %. Moreover, the company’s shares decreased by 13.4 % based on YTD, compared to 9.6 % of SPX.

If we look closely, the shares of the manufacturer of medical devices also fall behind the SPDR health care box (XLV) is 10.5 % over a period of 52 weeks.

BecTon Dickinson’s shares increased by 8.9 % on August 7 after the company reported the results of Q3 2025 stronger than expected, as the amended share profitability amounted to $ 3.68 and revenues of $ 5.5 billion. The growth was driven by an increase of 14.4 % in sales from its medical unit to $ 2.93 billion, as the expectations are topped, as the demand for drug delivery devices remained strong. In addition, BD raised the average profit forecast for 2025 to a range of $ 14.30 per share – $ 14.45 per share.

For the fiscal year ending in September 2025, analysts expect that the BDX modified EPS will grow by 9.1 % on an annual basis to $ 14.33. The company’s promising profits date. He won the unanimity estimates in the last four quarters.

Among the 18 analysts covering the shares, the consensus classification is a “moderate purchase”. This depends on seven categories “strong purchase”, one “moderate purchase”, and 10 “complexes”.

This configuration is slightly lower than three months, with eight “strong purchase” classifications on the arrow.

On August 11, Morgan Stanley raised its target price on BecTon Dickinson to $ 197 and kept the “weight gain” classification.

As of writing, the stock is traded less than the average price of $ 216.21. The goal of the high price of $ 285 involves a potential increase of 45.4 % of current price levels.

On the date of publication, Sohini Mondal did not have positions (either directly or indirectly) in any of the securities mentioned in this article. All information and data in this article are only for media purposes. This article was originally published on Barchart.com